ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,501 to 2,520 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) vs Enoxaparin 30 mg Twice a Day (Bid): serious adverse events106 of 1,526

131 of 1,508

-1.7 points

-3.7 to 0.2

3,034NCT00362232

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

Early Intervention vs Delayed Intervention: First Occurrence of Any Component of the Composite of Death, MI, or Refractory Ischemia151 of 1,593

186 of 1,438

-3.5 points

-5.7 to -1.2

3,031NCT00552513

Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes

Early Intervention vs Delayed Intervention: Composite of Death, Myocardial (re-) Infarction, or Stroke153 of 1,593

163 of 1,438

-1.7 points

-3.9 to 0.4

3,031NCT00552513

Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes

Arm I (Aspirin) vs Arm II (Placebo): deaths from any cause48 of 1,511

43 of 1,510

0.3 points

-0.9 to 1.6

3,021NCT02927249

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 vs Group 2: Placebo: Number of Participants With a Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 30 Visits (PP Set)71 of 1,525

67 of 1,494

0.2 points

-1.3 to 1.7

3,019NCT03964415

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Group 1: Ad26.Mos4.HIV + Clade C and Mosaic gp140 vs Group 2: Placebo: Number of Participants With Confirmed Human Immunodeficiency Virus (HIV)-1 Infections Diagnosed Between the Month 7 and Month 24 Visits (Per-protocol [PP] Set)65 of 1,525

58 of 1,494

0.4 points

-1.0 to 1.8

3,019NCT03964415

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Rivaroxaban 2.5 mg Twice Daily (BID) vs Acetylsalicylic Acid 100 mg Once Daily (OD): serious adverse events125 of 1,510

138 of 1,506

-0.9 points

-2.9 to 1.1

3,016NCT02293395

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

GSK3390107A Group vs Placebo+GSK3390107A Group: Number of Subjects With Serious Adverse Events (SAEs)11 of 1,509

18 of 1,504

-0.5 points

-1.2 to 0.3

3,013NCT02485301

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

GSK3390107A Group vs Placebo+GSK3390107A Group: deaths from any cause1 of 1,509

2 of 1,504

-0.1 points

-0.4 to 0.3

3,013NCT02485301

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

GSK3390107A Group vs Placebo+GSK3390107A Group: serious adverse events11 of 1,509

18 of 1,504

-0.5 points

-1.2 to 0.3

3,013NCT02485301

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

Daprodustat vs Darbepoetin Alfa: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)1,167 of 1,491

1,063 of 1,520

8.3 points

5.2 to 11.4

3,011NCT02876835

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Emergency Room (ER) Visits for Any Cause298 of 2,005

155 of 1,006

-0.5 points

-3.3 to 2.1

3,011NCT06291831

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Hospitalization for Any Cause137 of 2,005

123 of 1,006

-5.4 points

-7.8 to -3.2

3,011NCT06291831

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants Who Used Invasive Mechanical Ventilation (IMV)0 of 2,005

1 of 1,006

-0.1 points

-0.6 to 0.1

3,011NCT06291831

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Supplemental Oxygen Usage21 of 2,005

11 of 1,006

-0.0 points

-1.0 to 0.7

3,011NCT06291831

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With at Least 1 Pre-existing Comorbidities1,709 of 2,005

920 of 1,006

-6.2 points

-8.5 to -3.8

3,011NCT06291831

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Treated With Paxlovid vs Not Treated With Paxlovid: Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause3 of 2,005

1 of 1,006

0.1 points

-0.4 to 0.4

3,011NCT06291831

A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Apixiban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo: serious adverse events72 of 1,501

88 of 1,508

-1.0 points

-2.7 to 0.6

3,009NCT00452530

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Ischemic Target Lesion Revascularization98 of 2,257

54 of 749

-2.9 points

-5.1 to -1.0

3,006NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis181 of 2,257

59 of 749

0.1 points

-2.3 to 2.2

3,006NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=126"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=126

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00362232-sae",
        "title": "Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) vs Enoxaparin 30 mg Twice a Day (Bid): serious adverse events",
        "summary": "106 of 1526 against 131 of 1508; risk difference -1.7 points, 95% interval -3.7 to 0.2; NCT00362232, Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.",
        "record": "/library/comparisons/NCT00362232-sae",
        "nct_id": "NCT00362232",
        "kind": "serious-adverse-events",
        "participants": 3034,
        "risk_difference": {
          "value": -0.01740737908090012,
          "lower": -0.036659503884868605,
          "upper": 0.001727918840074432
        },
        "group_1": "106 of 1,526",
        "group_2": "131 of 1,508",
        "difference": "-1.7 points",
        "interval": "-3.7 to 0.2",
        "trial_title": "Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement."
      },
      {
        "id": "NCT00552513-0c3f1395",
        "title": "Early Intervention vs Delayed Intervention: First Occurrence of Any Component of the Composite of Death, MI, or Refractory Ischemia",
        "summary": "151 of 1593 against 186 of 1438; risk difference -3.5 points, 95% interval -5.7 to -1.2; NCT00552513, Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes",
        "record": "/library/comparisons/NCT00552513-0c3f1395",
        "nct_id": "NCT00552513",
        "kind": "outcome",
        "participants": 3031,
        "risk_difference": {
          "value": -0.03455660936625553,
          "lower": -0.05728322127511208,
          "upper": -0.012104102117430713
        },
        "group_1": "151 of 1,593",
        "group_2": "186 of 1,438",
        "difference": "-3.5 points",
        "interval": "-5.7 to -1.2",
        "trial_title": "Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=127",
  "request_id": "km8eBBvyBlv8IQwD"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?